<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01647737</url>
  </required_header>
  <id_info>
    <org_study_id>GHSU Lozenge Xerostomia Study</org_study_id>
    <nct_id>NCT01647737</nct_id>
  </id_info>
  <brief_title>Green Tea Lozenges for the Management of Dry Mouth</brief_title>
  <official_title>A Natural Formulation for Patients Diagnosed With Xerostomia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Augusta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Augusta University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this proposal is to investigate the effectiveness of a Medical College of Georgia
      patent pending formulation of natural plant extracts on patients with xerostomia. The major
      component of this formulation is green tea extract with a defined composition of polyphenols.
      Epidemiological studies suggest that phytochemicals in green tea possess beneficial effects
      on autoimmune and inflammatory diseases. Thus far, there is little evidence to indicate any
      marked and direct immunomodulatory effect of green tea on T or B lymphocytes. However, there
      is considerable evidence for green tea polyphenols (GTPs), major phytochemicals found in
      green tea extract, having properties consistent with effects on cells of tissues that would
      be protective towards local inflammation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with subjective complaints of xerostomia will be given a screening questionnaire to
      complete. If they meet the criteria on this screening form, the research coordinator will be
      notified and will meet with the patient either immediately or at a scheduled follow‐up
      appointment. The research coordinator will review the information and then explain the
      details of the study to the patient and obtain informed consent. Once the patient has signed
      the informed consent, the research coordinator will collect the demographic, medical history,
      and contact information from the patient. Any information missing will be noted for follow‐up
      investigation by the research coordinator. If a subject is of child bearing age, they will be
      asked to complete a urine pregnancy test prior to enrollment.[a] First appointment
      -Screening, consent. [b]Follow appointments- review, then Patients will do VAS questionnaire,
      QOL questionnaire, Sialometry will be done measuring unstimulated whole saliva and Stimulated
      whole saliva for 5 min each.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Salivary Flow From Baseline</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change in salivary flow in Xerostomic patients using Green tea lozenges</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Xerostomia</condition>
  <condition>Sjogren Syndrome</condition>
  <condition>Dry Mouth</condition>
  <arm_group>
    <arm_group_label>MighTeaFlow</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4-6 times daily lozenge containing green tea, jaborandi extracts, and 500 mg xylitol for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Xylitol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4-6 times daily lozenge containing jaborandi extract, and 500 mg xylitol for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>MighTeaFlow</intervention_name>
    <description>4-6 times daily</description>
    <arm_group_label>MighTeaFlow</arm_group_label>
    <other_name>Green Tea Lozenge</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Xylitol</intervention_name>
    <description>4-6 times daily</description>
    <arm_group_label>Xylitol</arm_group_label>
    <other_name>Aspartame</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. A complaint of dry mouth as assessed by a response of 30mm or greater on a Dry Mouth
             Visual Analog Scale (VAS)

          2. Clinical Diagnosis of primary or secondary Sjogren's syndrome.

          3. Over the age of 18.

          4. Taking less than three drugs associated with causing xerostomia or salivary gland
             hypofunction.

          5. Willing to use natural novel topical dry mouth products.

          6. Prior minor salivary gland biopsy and serology from Sjogren's Syndrome/Xerostomia
             work‐up.

          7. Willing to return for all study‐associated visits.

          8. Able to read, understand, and sign the informed consent.

        Exclusion Criteria:

          1. Have received radiation to the head and neck region.

          2. Unable to read and understand the consent form.

          3. On greater than three drugs associated with xerostomia or salivary gland hypofunction.

          4. Require dento‐alveolar surgery or extensive dental treatment during the course of the
             study.

          5. Require hospitalization for any medical problem during the course of the study.

          6. Unable to take green tea leaf extract and/or pilocarpus jaborandi leaf extract and/or
             xylitol because of allergy

          7. Uncontrolled medical conditions that require changes in medication during the course
             of the study.

          8. Regularly consume green tea and/or components of pilocarpus jaborandi.

          9. Are pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott S De Rossi, DMD</last_name>
    <role>Principal Investigator</role>
    <affiliation>GHSU</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GHSU Center for Oral Medicine</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 14, 2012</study_first_submitted>
  <study_first_submitted_qc>July 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 24, 2012</study_first_posted>
  <results_first_submitted>January 23, 2015</results_first_submitted>
  <results_first_submitted_qc>March 17, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 18, 2015</results_first_posted>
  <last_update_submitted>March 17, 2015</last_update_submitted>
  <last_update_submitted_qc>March 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Augusta University</investigator_affiliation>
    <investigator_full_name>Scott DeRossi</investigator_full_name>
    <investigator_title>Chairman, Diagnostic Sciences</investigator_title>
  </responsible_party>
  <keyword>Xerostomia</keyword>
  <keyword>Sjogren syndrome</keyword>
  <keyword>dry mouth</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sjogren's Syndrome</mesh_term>
    <mesh_term>Xerostomia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Potential candidates were identified from a pool of previously diagnosed subjects and new subjects referred to the Clinical Center for Oral Medicine, School of Dentistry, Georgia Regents University</recruitment_details>
      <pre_assignment_details>Subjects had a diagnosis of Xerostomia</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Green Tea Lozenge</title>
          <description>GTP
Green tea lozenge: 4-6 times daily</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Xylitol lozenge 4 - 6 times daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Consented subjects diagnosed with Xerostomia and meeting all inclusion exclusion criteria</population>
      <group_list>
        <group group_id="B1">
          <title>Green Tea Lozenge</title>
          <description>GTP
Green tea lozenge: 4-6 times daily</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Xylitol
Green tea lozenge: 4-6 times daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Salivary Flow From Baseline</title>
        <description>Change in salivary flow in Xerostomic patients using Green tea lozenges</description>
        <time_frame>8 weeks</time_frame>
        <population>Enrolled subjects completing 8 weeks of treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Green Tea Lozenge</title>
            <description>GTP
Green tea lozenge: 4-6 times daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Xylitol lozenge 4 - 6 times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Salivary Flow From Baseline</title>
          <description>Change in salivary flow in Xerostomic patients using Green tea lozenges</description>
          <population>Enrolled subjects completing 8 weeks of treatment</population>
          <units>ml/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" spread="0.051"/>
                    <measurement group_id="O2" value="0.10" spread="0.278"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.66" spread="0.168"/>
                    <measurement group_id="O2" value="0.04" spread="0.142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected over a period of 27 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>MighTeaFlow</title>
          <description>4-6 times daily lozenge containing green tea, jaborandi extracts, and 500 mg xylitol for 8 weeks
MighTeaFlow: 4-6 times daily</description>
        </group>
        <group group_id="E2">
          <title>Xylitol</title>
          <description>4-6 times daily lozenge containing jaborandi extract, and 500 mg xylitol for 8 weeks
Xylitol: 4-6 times daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic Rhinitis</sub_title>
                <description>itching and scratchiness in the throat</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Scot DeRossi, Chairman of the ORal Medicine &amp; Diagnostic Sciences Department</name_or_title>
      <organization>Georgia Regents University</organization>
      <phone>706-721-2607</phone>
      <email>Sderossi@gru.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

